番茄社区

Mike Bassett

Mike Bassett

Authors >

Mike Bassett

Mike Bassett is a staff writer for 番茄社区 focusing on oncology and hematology. He has over 20 years of journalism experience, including a dozen years covering medicine and healthcare. Based in Massachusetts, he has degrees from Boston University and George Washington University and spends much of his free time either watching or playing soccer.

Connect:

email image

Latest from Mike Bassett

FDA APPROVED zanidatamab (Ziihera) over a computer rendering of the gall bladder.

FDA Approves Zanidatamab for Biliary Tract Cancer

New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease

AASLD over a photo of San Diego Convention Center in San Diego, CA.

Novel Therapy Reduced Liver Fat, Improved Fibrosis in MASH

Liver fat reductions were sustained for up to a year with the thyroid hormone receptor agonist

AASLD over a photo of San Diego Convention Center in San Diego, CA.

'A Watershed Moment': GLP-1 Drug Succeeds in Late-Stage MASH Trial

First positive phase III study for a GLP-1 agonist in chronic liver disease

AASLD over a photo of San Diego Convention Center in San Diego, CA.

Tapered Steroid Dosing Safe, Effective in Severe Alcohol-Associated Hepatitis

Notably, tapering reduced the risk of infection compared with a fixed dose

AASLD over a photo of San Diego Convention Center in San Diego, CA.

New MELD Model Improves Access to Liver Transplant for Women

A greater proportion of women on the waitlist and undergoing transplant since adoption

AASLD over a photo of San Diego Convention Center in San Diego, CA.

Immunotherapy Shows Promise in Downstaging Liver Tumors Prior to Transplant

78% of patients in prospective study had tumor downstaging with immune checkpoint inhibitors

AASLD over a photo of San Diego Convention Center in San Diego, CA.

Fecal Therapy Shows Survival Benefit in Severe Alcoholic Hepatitis

Improved markers of disease severity as well in small trial of steroid-ineligible patients

A computer rendering of ovarian cancer.

Adding HIPEC Boosts Survival in Recurrent Ovarian Cancer

Results "signal a paradigm shift," expert says

A computer rendering of the pembrolizumab antibody.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

But absence of significant OS benefit raises questions about long-term benefit, expert says

A photo of a female nurse interacting with a little girl who is receiving chemotherapy.

Electronic Symptom Screening in Kids With Cancer Boosts Quality of Care

Improvements seen in pain, neuropathy, and cognitive function

1

鈥�